Regular paperPituitary adenylate cyclase-activating polypeptide: a novel, long-lasting, endothelium-independent vasorelaxant
References (9)
- et al.
A novel peptide which stimulates adenylate cyclase: molecular cloning and characterization of the ovine and human cDNA's
Biochem. Biophys. Res. Commun.
(1990) - et al.
Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells
Biochem. Biophys. Res. Commun.
(1989) - et al.
A highly sensitive adenylate cyclase assay
Anal. Biochem.
(1974) - et al.
Prostacyclin analogues reduce ADP-ribosylation of the α-subunit of the regulatory G5-protein and diminish adenosine (A2) responsiveness of platelets
Br. J. Pharmacol.
(1987)
Cited by (89)
Pituitary Adenylate Cyclase-Activating Polypeptide Is Upregulated in Murine Skin Inflammation and Mediates Transient Receptor Potential Vanilloid-1-Induced Neurogenic Edema
2015, Journal of Investigative DermatologyCitation Excerpt :Furthermore, its direct inhibitory effect on plasma extravasation and edema at the level of the vascular endothelium can also be assumed. This is supported by the presence of PAC-1 on endothelial cells (Abu-Hamdan et al., 2006), but numerous data indicate a relaxing action of PACAP on the vascular smooth muscle (Fahrenkrug et al., 2000; Dalsgaard et al., 2003), independent of the endothelium (Warren et al., 1991, 1992). On the basis of these data, the role of endogenous PACAP in acute neurogenic edema formation in the skin is pro-inflammatory, whereas the effect of the exogenous peripherally administered peptide is inhibitory on sensory neuropeptide release (Nemeth et al., 2006; Helyes et al., 2007).
Pituitary adenylate cyclase activating polypeptide: An important vascular regulator in human skin in vivo
2010, American Journal of PathologyCitation Excerpt :This role is supported by studies in dogs, in which high doses of PACAP1-27 and PACAP1-38 induced hypertension after a transient hypotension, indicating a concentration-dependent effect of PACAP in all body vessels.50 Others,49 however, did not observe hypertension at concentrations of 10−12 mol/L, but showed that both PACAP1-38 and PACAP1-27 stimulated a marked vasodilatation in humans, which was 100× higher than that for VIP. In accordance with our study, a study investigating the systemic vasodepressive effect of PACAP in rodents demonstrated that the effects of PACAP were significantly weaker than those of VIP, indicating a limited systemic vasodepressive effect of PACAP both in rodents and humans at moderate physiological concentrations.51,52